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ABSTRACT
Effects of Combined Bevacizumab and Paclitaxel on Tumor Interstitial Fluid Pressure in a
Preclinical Breast Cancer Model
by
Ricardo H. Alvarez
Several mechanisms of cell resistance are often accountable for unsuccessful chemotherapy against
cancer. Another reason, which has received increased attention, is the inefficient transport of
anticancer drugs into tumor tissue. These impaired transports of chemotherapy into the tumor have
been attributed to abnormal microvasculature and to pathologically increased tumor hypertension also
called: interstitial fluid pressure (IFP). The pathophysiological processes leading to elevated tumor
IFP are poorly understood. Here, in a preclinical breast cancer model, it is argued that a condition of
raised IFP is a major factor in preventing optimal access of systemically administered chemotherapy
agents. In our experimental model, we used a GILM2 human breast cancer in xenografts; mice were
treated with different doses of paclitaxel –a widely used antimicrotubular agent, and bevacizumab –
monoclonal antibody against vascular endothelial growth factor (VEGF). The proposed research
project is designed to test the hypothesis that paclitaxel in combination with bevacizumab decreases
the tumor IPF by restoring tumor permeability and increasing chemotherapy delivery. We
demonstrated that the combination of paclitaxel and bevacizumab produced greater tumor control
than either agent given alone and this combination reduced the IFP, producing an increment of 75%
of apoptosis compared with the control arm. In addition, the intra-tumor paclitaxel quantification by
liquid chromatography/Mass Spectrometry (LC/MS) demonstrated that lower dose of both agents
showed a synergistic effect compared with high dose of treatment, where there is no significantly
increase of paclitaxel into the tumor. These preclinical results are likely to have broad implications
for the utility of anti-angiogenic therapies alone and in combination with chemotherapeutic agents.
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Chapter 1
1. Introduction: Breast Cancer 2010
In the United States, breast cancer is the most commonly diagnosed cancer and is the second
leading cause of death in women. [1] It is estimated that 207,090 new patients of breast cancer
will be diagnosed in the United States in 2010 representing 28% of all female cancers
incidence, and 39,840 deaths representing 15% of all female cancer death. [2] Breast cancer is
also an important public health problem in the world; in 2007, 1.3 million women were
diagnosed with breast cancer worldwide, and almost 465,000 died from the disease.

[3]

Over

the past few years, breast cancer mortality has been steadily decreasing due to a variety of
reasons, including success of mammography screening and the availability of newer
cytotoxic chemotherapy and targeted agents. [4, 5]
The treatment of MBC is palliative and rarely curative. Therefore, the goals of the
treatment consist in alleviation of symptoms and improvement or maintenance of good
quality of life. This has led to much interest in the understanding of the pathogenesis of
breast cancer metastasis and the mechanism of tumor resistance.
Although the use of anthracyclines and taxanes has led to an increase in survival of
patients with metastatic or locally advanced disease, the benefit from third-line therapies is
less clear. Patients who have disease that is resistant to these therapies, or who develop
toxicities causing cessation, may then receive other agents that are of limited benefit.
Although there is no widely accepted standard of care, current options for patients that who
failed anthracyclines and taxanes include the vinca alkaloids,

[6, 7]

gemcitabine,

capecitabine, [9, 10] nanoparticle albumin-bound paclitaxel, [11] and recently, ixabepilone
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[8]

[12-15]

The principal cause of death from cancer is metastases that are resistant to
conventional therapies. Approximately, 1 out of 5 patients with diagnosis a of breast cancer
will develop metastasis in 5 years. [16] The prognosis of patients with metastatic breast cancer
remains poor; the 5-year survival rate is only 26% in the United States. [17]
Because of the lack of clinical responses to anti-VEGF treatment in solid tumors, with
the exception of renal cell and hepatocellular carcinoma, several investigators started
combining anti-VEGF treatments with conventional cytotoxic drugs. With this combination,
the aim is to target two compartments: the stroma and endothelial cells and the cancer cells.
Currently, in the United States, the Food and Drug Agency approved in three of the
most common solid tumors -breast, lung and colorectal cancer- the combination of antiVEGF (bevacizumab) in combination with chemotherapy as front-line treatment for
advanced disease.

2. Mechanism of Resistance to Cancer Treatment
One of the principal factors responsible for failure to respond to cancer treatment is drug
resistance. There are two types of tumor resistance: a) intrinsic resistance to de novo
treatment with chemotherapy, and b) secondary or acquired resistance, for the cases when
tumor initially responded to treatment and became resistant during, or right after treatment.
[18]

Drug resistance, whether intrinsic or acquired, is believed to cause treatment failure in

over 90% of patients with metastatic cancer, and resistant micrometastatic tumor cells may
also reduce the effectiveness of chemotherapy in the adjuvant setting.

[19]

Clearly, if drug

resistance could be overcome, the impact on survival of the cancer patient would be highly
significant.
2

There are many factors that affect drug sensitivity. These include mechanisms such as
those that limit the amount of drug reaching the tumors and those affecting the tumor
microenvironment. [18] The classical description of cellular mechanisms of resistance involve
multiple processes, including: drug influx and efflux, drug inactivation, drug targets, DNA
damage repair, cell cycle arrest versus apoptosis, induction of apoptosis, and pro-survival
signaling. [20]

3. Tumor Microenvironment
More than a century ago, Stephen Paget, a British surgeon, proposed that the
microenvironment of a developing tumor is a crucial regulator of carcinogenesis and he
elaborated his famous “seed and soil” hypothesis.

[21]

He hypothesized that cancer cells (the

seeds) were interconnected by several types of signals with the stroma cells (the soil). After
reviewed 735 autopsies of patients with breast cancer in 1889, he concluded that the pattern
of metastasis is not a random process, instead was a complex and regulated process which
depends on the tumor stroma. This seminal observation was demonstrated a century later
with multiple experiments. [22]
An influential publication by Dr. Dvorak in 1986, clearly showed that the growth of
carcinomas beyond a diameter of about 1-2 mm requires the formation of a supporting tumor
stroma to ensure the supply of nutrients for tumor cell survival and growth.

[23]

The tumor

stroma microenvironment may differ between tumor types and disease stages. Tumor stroma
represents between 20% to 50% of the mass in breast, lung, and colorectal carcinomas.
However, in tumors with extensive desmoplastic component, the stroma can represent 90%
of the mass of tumor.
3

It is important to mention that the mass and composition of the stroma differs
between tumors and is not related with the degree of tumor malignancy. [24]
The tumor stroma is composed of a variety of cells which are interconnected by
several types of cross-talk signaling. The most common resident cell types are fibroblast,
smooth muscle cells, immune and inflammatory cells, lipocytes and endothelial cells. [25] The
active interconnections between cancer cells and the tumor stroma are responsible in part for
the strong influences that stroma cells impose on cancer cells. The traditional concept that
cells immediately adjacent to a tumor are passive structural elements that elicit an immune
response in an attempt to resist and reject the tumor has now been challenged by a
considerable body of evidence from many investigators.[26] So, it is becoming apparent that
the tumor microenvironment exerts an important role in the neoplastic phenotype.
In order to maintain a tissue homeostasis, all tissues require an extracellular network
to

provide

structural

support

and

facilitate

the

cell-cell

communication.

The

microenvironment of solid tumors has several characteristics that distinguish it from the
corresponding normal tissue. These characteristics are thought to become established due to
an abnormal relationship between poorly formed tumor vasculature and the physiologic
characteristics of the cells within the tumor.

[27]

In order to obtain nutrients for their growth

and metastatic potential, cancer cells will utilize the host blood vessels, sprout new vessels
from existing ones (angiogenesis), and recruit endothelial cells from the bone marrow
(postnatal vasculogenesis). [28] The anomalous morphology of blood vessels is responsible for
the irregular blood flow which results in chaotic blood vessel networks. This interaction
between abnormal blood vessels and cancer cells is responsible for the microenvironmental
4

hallmarks of solid tumors consisting of: low oxygen tension or hypoxia, low extracellular pH
or acidosis, and high interstitial fluid pressure.
vessels, hypoxia and is depicted in Figure 1.
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[19]

The relationship between abnormal blood

Figure 1: Microenvironment Conditions of the Tumor Present Barriers to Therapy.
Confocal micrographs from tumor section of human breast cancer xenograft. Blood vessels
stained for CD31 (red), pericytes for desmin (green), and hypoxia for HypoxyProbe
(brown)
a) The tumor microenvironment is typically hypoxic with chaotic vasculature with unstable
endothelium, loose pericytes, and leaky vessels. Poor oxygen delivery by the defective
vasculature and oxygen consumption by the tumor cells results in hypoxic areas. In addition,
the hyperpermeable blood vessels produce a hypertensive extracellular matrix (ECM); Dark
brown color represents tissue hypoxia stained with HypoxyProbe.
(b) Relationship between abnormal blood vessels and pericytes. Dual immunofluorescence
staining for CD31 (red) and desmin (green) was performed to visualize endothelial cells and
pericytes, respectively. The white rectangle shows the process of “sprouting angiogenesis”.
Endothelial sprouts tipped by filopodia are abundant on blood vessels and are currently
known as a molecular target for the anti-VEGF treatments. Sprouting angiogenesis is
characterized by non-mitotic endothelial cell activity, high reversibility, and is always
accompanied by pericytes.
Images were taken by the author of this thesis at the Cancer Biology Department at
original magnification x400 and x100 respectively.
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Figure 1
a. Tumor Microenvironment. Relationship between endothelial cells (red), pericytes
(green) and tissue hypoxia (dark brown).

Hypoxia

Hypoxia

CD31
Desmin

Hypoxia

b. Tumor Blood Vessels: Endothelial Cells and Pericytes.

Endothelial cells: CD31
Pericytes: Desmin
Tumor cells: Hoechst
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These physiological characteristics of tumor microenvironment have been shown to act as an
impressive obstacle to the delivery and efficacy of cancer therapy. Novel molecular strategies
designed to understand the correct structure and function of tumor vessels and how to
interfere with these physiological barriers will improve cancer treatment.

4. Stromal Microenvironment as Cause of Drug Resistance
In order for an anticancer agent to be therapeutically effective, it should be uniformly
distributed through the tumor circulation, cross the vessel wall, and pass through the ECM
and finally arrive in the stroma and cancer cells with adequate concentration to cause tumor
cell lethality.
Drug resistance remains a principal problem impeding the success of chemotherapy
in the treatment of cancer.

[29]

Currently, most of the cancers that are treated with

conventional anticancer therapies become resistant to these agents. Two important
mechanism of resistance have been identified including intrinsic and acquired resistance. [18]
Intrinsic resistance to anticancer drugs, or resistance developed during chemotherapy,
remains a major obstacle to successful treatment. In the current literature a large number of
published studies about resistance of cancers to chemotherapy focus on cellular and genetic
mechanisms as principal factors of resistance, whereas very few describe the role of
microenvironment factors. [30]
There is a generally accepted hypothesis that tumor cells are genetically unstable and
can mutate and that drug resistance of human tumors arises because of the selection of
mutant drug-resistant cell during tumor progression, or following exposure to chemotherapy.

8

This resistance in the clinic manifests itself as lack of initial response –mentioned as
refractoriness, or as regrowth after initial response (relapse).

9

Chapter 2
1. Physiological Barriers of Drug Resistance
The tumor microenvironment possesses several properties that distinguish it from the normal
tissues. These differences arise from the irregular characteristics of the blood vessels and the
physiologic properties of the cells within the tumor.

[27]

The tumor microenvironment has

been recently recognized as a physiological barrier to conventional chemotherapy and
radiation-based therapies. These barriers include, tumor hypoxia, tumor acidity (low pH), and
high tumor IFP. (Figure 2)
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Figure 2 - Tumor acidosis and Hypoxia
a) Diagrammatic representation of tumor cells and the extracellular matrix surrounding a
capillary.
b) Schematic representation of the gradient of oxygen concentration (pO2; dashed line) and
pH (dotted line) in relation to nearest tumor blood vessel.
Graphic obtained with permission from Tedran and collaborators. [29]
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Figure 2 - Tumor Acidosis and Hypoxia
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Tumor Hypoxia
Tumor hypoxia is a universal feature of solid tumors. In contrast to normal tissue, the tumor
blood vessels are characterized by the utilization of oxygen which is larger than the oxygen
release. [31, 32] This imbalance is responsible for inconsistent tissue perfusion, producing high
variation of oxygen concentration throughout the tumor mass. Two main causes of tumor
hypoxia have been recognized: permanent limitations in oxygen diffusion results in chronic
hypoxia, and transient limitations in blood perfusion result in acute hypoxia.[32] More
importantly, most of the assays of tumor hypoxia currently available do not distinguish
between chronic and acute hypoxia. From the clinical point of view, tumor hypoxia has been
implicated in the resistance to treatment, especially radiation therapy. In addition, hypoxia is
also responsible for malignant phenotype, and is predictive of metastasis and poor outcome
in a variety of tumor types. [33-35]
Hypoxia-inducible factor-1 (HIF-1) is a transcription factor that regulates multiple
genes that are responsible for the adaption of cells to live in normoxia (~21% O2) to hypoxia
(~1% O2) conditions.

[36, 37]

Since the discovery of HIF, more than 2 decades ago, the

knowledge of the role of HIF in tumor biology has grown exponentially. Because the broad
spectrum of influences of HIF-1, it is actually considered an important target for many
tumors. In a very elegant publication, Cairns et al

[38]

using RKO and Su.86 cell lines as

preclinical models demonstrated that blocking the HIF-1 pathway represented a novel
microenvironment target for solid tumors. In a retrospective review of 150 patients with early
invasive breast cancer, treated between 1985 and 1993 in Holland, HIF-1 alpha expression
correlated with multiple clinicopathologic variables.
13

[39]

The results showed that a high level

of HIF-1 alpha was associated independently with shortened disease free survival (p = 0.004)
and overall survival (p = 0.008) in patients with lymph node negative breast cancer.

Tumor Acidosis
The microenvironment tumor acidosis (pHe) is low compared with the normal tissues.
Initially it was thought that the tumor acidosis was the result of accumulation of lactate, the
product of anaerobic glycolysis associated with tumor cells. Many of the anti-neoplastic
chemotherapy drugs used commonly for cancer treatment are influenced by the
microenvironment acidity. In general, the diffusion of drugs into cells occurs by passive
diffusion when they are uncharged. However, when drugs are highly polar with acidic or
basic groups the cellular uptake depends on the pHe. Thus, basic drugs like doxorubicin,
mitoxantrone, and vinblastine have reduced activity in a low pHe due to decreased drug
uptake.
In the past, preclinical studies using direct measurement of the pH within tumor
models with electrode-based techniques showed that tumor cells can carry out glycolysis and
produce lactate are still able to generate an acidic environment.
techniques with

31

[40, 41]

Using more modern

P magnetic resonance spectroscopy to measure the characteristics of pH-

dependent microenvironment in solid tumors, it was determined that the acidity within the
tumor is a combination of the pHe and the internal, intracellular pH (pHi). Cells within the
tumor are capable of maintaining a reasonably neutral cytosolic pH in the face of external
acidosis. [42]
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Chapter 3
1. Interstitial Fluid Pressure and Transvascular Transport
The interstitium
New strategies to improve the distribution of drugs between normal and tumor tissues that
reduce toxicities associated with chemotherapy regimens for solid tumors in conjunction with
increase efficacy are warranted. A potential target is tumor IFP.
The ECM or interstitium consists of the collective spaces between cells, and accounts
for approximately one sixth of the total body volume.

[43]

The extracellular compartment is

composed of a collagen fiber scaffold that contains a gel phase made up of hyaluronan,
glycosaminoglycans (GAGs), salts, and plasma-derived proteins. [43] The collagen structure is
thought to physically restrain the intrinsic tendency of the hyaluronan and the
glycosaminoglycans to swell, thus reaching equilibrium.

[44, 45]

Interstitial fluid, made up of water and solutes, acts as the transport medium for the
exchange of nutrients, waste products, and oxygen. IFP is the result of oncotic pressure in the
interstitial space, oncotic and hydrostatic pressures in the microvascular space, the reflection
coefficient, and the hydraulic conductivity of the vascular wall and interstitial space.
Together these forces determine the net filtration pressure across the capillary plasma
membrane and are determined by the Starling equation: [46]
Jv = Kf [(Pc-Pif) - σ(COPc-COPif)],
Where fluid transport across the capillary wall can be described quantitatively, Jv is net
capillary fluid filtration, Kf is the capillary filtration coefficient, Pc and Pif are the hydrostatic
15

pressures in capillary and interstitium, respectively, COPc and COPif are the corresponding
colloid osmotic pressures, and σ is the capillary reflection coefficient for proteins.
This traditional concept of transcapillary fluid flux is the product of the pressure
imbalance across the capillary wall, and does not include cells in the regulation of
interstitium. A new concept in the interstitium fluid regulation included connective tissue
cells that are not organ specific but are an integral part of the extracellular matrix. (Figure 3)
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Figure 3: Overview of the transcapillary-interstitial fluid exchange system.
The transcapillary hydrostatic (P) and colloid osmotic pressure (COP) determines capillary
fluid flux. Subscripts “c” and “if” denote plasma and capillary reflection coefficient,
respectively. The capillary net filtration pressure is normally 0.5 to 1 mmHg and results in a
net fluid filtration (Jv) that is removed by lymph flow. Collagen and hyaluronan are abundant
structural component of loose connective tissues. Graphic obtained with permission from
Wiig and collaborators. [45]
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Figure 3 - Overview of the transcapillary-interstitial fluid exchange system
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Regulation of the IFP
The normal tissues possess a very sensitive regulation of ECM fluid. For instance, in most
tissues of the body, the IFP under normal conditions is slightly negative, e.g. about -1 mmHg
in the skin. However, under pathological conditions, such as burn injuries, urticaria or
inflammation, the net filtration pressure increases tremendously due to a fall in the IFP to as
low as -150 mmHg, resulting in edema formation.

[47]

This example illustrates that there is

also an active control of the transcapillary exchange of fluids by the interstitium. Moreover, it
also implies that cells in the interstitial compartment, e.g. fibroblasts, and pericytes are
important regulators of the IFP. One possibility for the cells in the connective tissues to exert
a controlling force over the IFP is via the contacts made between the cell and ECM
constituents through integrins.

[44]

Another possibility is related to the mesodermal origin of

such cells and the contraction capacity eliciting changes in the ECM.
IFP is Elevated in Solid Tumors
The clinical measurement of IFP in normal subcutaneous tissues and muscle tissues show a
range from -2 to 4 mm Hg.

[48, 49]

In contrast, solid tumors have elevated IFP compared with

normal tissue, with a steep rise in pressure starting at the periphery of the tumor. Interstitial
pressure was first noted to be elevated in animal tumors in 1950 by Young and colleagues,
[50]

and the first data on interstitial tumor pressure in humans were published in 1990.

[51, 52]

These studies suggest that many human tumor nodules have interstitial pressures much
greater than in normal tissues. The precise cause of increased tumor IFP is not well
understood: a number of mechanisms have been hypothesized, yet none experimentally
confirmed. Explanations included scarcity of lymphatic vessels, tumor fibrosis, and the leaky
nature of tumor vessels, caused by an increased signaling from vascular endothelial growth
19

factor receptor. [53] Implantation of the same tumor cell line at diverse sites in mice produces
dissimilar IFPs, suggesting that the microenvironment impacts tumor IFP. [54] Nowadays, we
accept that the cause of high tumor IFP is multifactorial.
Consequences of Elevated IFP
Elevated IFP in tumors is a consequence of severe microvascular, lymphatic, and interstitial
abnormalities. In accordance with an increased IFP, the oncotic pressure of tumor interstitial
fluid is also elevated compared to normal tissue and is close to that of plasma, indicating that
there is a reduced transport of fluids into tumors compared with normal tissues.

[55]

This

could affect the distribution of therapeutic antibodies into tumors because macromolecules
are thought to be transported preferentially through convection. However, a high tumor IFP
could also conceivably hinder the delivery of low molecular weight compounds, which are
thought to be transported mainly by diffusion in normal tissue. The microvascular exchange
barrier in tumors is nonselective, because of its leaky nature, and thereby favors convective
transport of water-soluble low molecular weight agents. Also, the increased water content in
tumors may facilitate diffusion of molecules through the tumor interstitium.

[56]

Indeed,

studies in experimental models have shown that lowering tumor IFP, either by
pharmacologic interference or by increasing the transcapillary hydrostatic pressure gradient,
is paralleled by an increased transport of both macromolecules and low molecular weight
compounds.

[56, 57]

Local delivery of prostaglandin E1 to tumors in rats lowered the IFP and

enhanced the penetration of 51Cr-EDTA.

[56]

Targeted delivery of tumor necrosis factor-α to

tumor vessels in mice enhanced the penetration of doxorubicin into tumors.
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[57]

In a series of patients with cervical carcinoma there was a correlation between
interstitial pressure and the oxygenation status of the tumor and an inverse correlation with
tumor response to radiation therapy.

[58]

In another study in patients with cervical cancer,

tumor IFP was a strongly independent prognostic marker for radiation therapy of cervical
[59]

cancer.

In this study, 102 eligible patients with locally advanced cervical cancer were

evaluated during treatment with radiation therapy. The IFP assessment was done using a
wick-in-needle technique. Patients with high IFP were more likely to recur both locally and
at distant sites. In addition, patients with high IFP were significantly more likely than those
with low IFP to recur after radiotherapy and die of progressive disease.
Role of Platelet-Derived Growth Factor Receptor in tumor IFP Regulation
Platelet-derived growth factor (PDGF) is a mitogen and a chemoattractant for cells of
mesenchymal origin, e.g. fibroblasts and smooth muscle cells, which acts by binding two
structurally related tyrosine kinase receptors. Different roles in the paracrine stimulation of
tumor stroma have been described for PDGF. [60]
The well-documented PDGF β-receptor expression in the stromal compartment in
many common solid tumors (lung, breast, colon), which also are characterized by tumor
interstitial hypertension, is consistent with a role of PDGF β-receptors in the control of tumor
IFP.

[61]

The tyrosine kinase inhibitor imatinib inhibits the kinase activities of the PDGF

receptors, c-Kit, ABL, and ARG with similar potencies.

[62]

Imatinib –a potent inhibitor of

BCR/ABL oncoprotein and c-Kit receptor- is currently used in the treatment of chronic
myelogenous leukemia and gastrointestinal stromal tumors. Three preclinical studies have
examined the effect of imatinib on the IFP in experimental tumor models, [63-65] and analyzed
21

in a separate publication. [66] The first of these studies found that rats with colonic carcinomas
treated with imatinib exhibited a reduced IFP measured by the wick-in-needle technique.
Treated tumors showed a mean IFP of 11.3 +/- 1.1 mm Hg, whereas untreated tumors
displayed a mean IFP of 16.8 +/- 0.9 mm Hg (p < 0.01). Subsequently treatment with
imatinib increased the uptake of freely diffusible tracer 51Cr-EDTA into the tumors (p < 0.05)
compared with untreated animals. [63] The second study in mice showed that imatinib induced
lowering of IFP was paralleled by an enhanced tumor content of paclitaxel.

[64]

Mice with

KAT-4 tumors were injected with [3H] paclitaxel and radioactivity was measured 8 or 24
hours. Mice treated with imatinib significantly increased tumor uptake of [3H] paclitaxel
compared with the control group (p < 0.05). Imatinib had no direct effect on tumor growth,
but the combination of imatinib and paclitaxel, increased the efficacy of chemotherapy. In
the third study, mice injected with human thyroid carcinomas were treated with various doses
of the epothilone B (EPO906 or patupilone a novel anti-microtubular agent), alone or in
combination with imatinib.

[65]

The combination was more effective than chemotherapy

alone, and tumors treated with the combination were more than 40% smaller. In addition,
there was a tumor-specific, three-fold increase in tumor level of EPO906. Interestingly,
various treatment regimens of imatinib showed a correlation between the ability of the
treatment to lower tumor IFP and enhanced tumor uptake and efficacy of EPO906.
These studies clearly establish that inhibition of PDGF receptor signaling is a novel
strategy for enhancement of chemotherapeutic effects on solid tumors. These data also
suggest that the reduction of tumor IFP is related to the drug uptake and is one of the
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mechanisms of tumor sensitivity. There are currently several clinical trials in advanced solid
tumors, exploring the combination of standard chemotherapy with imatinib.
IFP and transvascular transport in tumors
Extravasation of materials from the blood vessels can occur by diffusion and convection and
is described by the following equation: [67]
J = PS (Cp - Ci) + Lp S) 1-σ) [(Pv - pi) - σ (πv - πi)] Cp
J is the flux (mass per unit volume) of materials crossing the vessel wall, P is the vascular
permeability, S is the vessels’ surface area, Cp – Ci is the concentration difference of the
material between the plasma and the interstitial space, Lp is the hydraulic conductivity of the
vessel wall, Pv – pi is the difference between microvascular and IFP, σ is the osmotic
reflection coefficient, and πv - πI is the osmotic pressure difference across the wall. The
vascular permeability depends on the properties of the particle (size, charge and
configuration) and the vessel wall (pore size, charge and arrangement). It decreases as the
particle size increases and becomes zero when the particle size is larger than the pore cut-off
size. The hydraulic conductivity is a property of the morphology of the wall surface occupied
by pores.
Young and collaborators, showing that the “tissue pressure” of testicular tumors is
substantially higher than in normal tissue, did the first preclinical tumor IFP assessment.

[50]

Since then, multiple other investigators have demonstrated that the IFP of most, if not all,
experimental and clinical tumors is elevated.

[68]

During the last four decades multiple

investigators have measured tumor IFP in several tumor types. For instance, pressures of up
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to 60 mmHg were found in melanomas [69-71] and the mean IFP of head and neck carcinomas
was shown in a large number of patients to be 19 mmHg. [52] Still, the etiology of tumor IFP
is unclear, the tumor microvascular pressure has been found to correlate with the IFP.

[69]

This evidence support the concept that the stromal compartment is likely to be an important
determinant of tumor IFP, since implantation of the same tumor cell line at diverse sites gives
rise to dissimilar absolute pressures. [54]
One of the consequences of the high IFP in tumor tissue has been proposed to be an
impaired transvascular transport of fluids and molecules into the tumor interstitium.

[60]

Several investigators demonstrated that the tumor interstitium has unique biophysical
properties provide experimental support for this proposal. [72, 73]
Many investigators have used pharmacological intervention to lower the tumor IFP as
a viable strategy to increase the uptake of anti-cancer drugs into tumors, thereby achieving
higher quantities of effective treatment into the tumor. Several agents administered either
locally or systemically, have been shown to alleviate the interstitial hypertension in the
experimental setting. Various substances, such as nicotinamide and a bradykinin B2 agonist,
act on the microvasculature, whereas others, such as hyaluronidase, affect the
microenvironment. It is notable, however, that the precise mechanism of action in most
treatments is not well understood.
Tumor Angiogenesis and Interstitial Hypertension
The growth of neoplastic cells in a confined and stiff interstitial matrix can induce solid
stress, causing an increase in microvascular pressure (MVP) and IFP. The MVP is dependent
on arteriovenous pressure differences and the geometric and viscous resistance to blood
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flows. Boucher, et al, hypothesized that MVP is a major determinant of IFP due to the high
permeability of tumor vessel and the lack of functional lymphatics. [69, 74] The same group of
investigators

[75]

reported that taxanes inhibit the growth of murine mammary carcinoma

(MCa-IV) and the human soft tissue sarcoma (HSTS-26T). After treatment with paclitaxel
blood vessels were measured at 48 and 96 hours, demonstrating that the diameter increased
significantly. The increase of vascular diameter was associated with reductions in MVP and
IFP. Thus, taxanes might be responsible for the increase of delivery of therapeutic agents into
the tumor. [76]
VEGF is a potent angiogenic factor released by a variety of normal and neoplastic
cells following a hypoxic stimulus. VEGF was originally discovered as a vascular
permeability factor (VPF) a glycoprotein secreted by tumor cells that potently stimulates
ascites formation and vascular leak.[77] This vascular leak, most probably contributes to the
elevated interstitial pressure of ECM commonly seen in solid tumors. A recent report showed
that blocking the VEGF signaling by a VEGF-receptor-2 antibody decreases the IFP in a
variety of tumor models, not by restoring the lymphatic function, but by producing a
morphologically and functionally normalized vascular network.

[78]

The same investigators

also report that an anti-VEGF antibody can lower IFP in rectal carcinomas in patients.

[79]

Thus, this process of “vascular normalization” might be responsible for the increase of
survival rates in animal studies and for the efficacy demonstrated with patients with rectal
cancer after treatment with combination of bevacizumab and cytotoxic chemotherapy.
One of the main functions of pericytes consists in providing stability of blood vessels.
It is also critical in the development of microvessels in many organs. Pericytes –as well as
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endothelial cells, are also sensitive to anti-VEGF treatments. A recent study demonstrated
that pericyte density is affected by anti-VEGF therapies.

[80]

Therapeutic benefits were

recently observed after combination of the VEGF antagonist with imatinib in a genetic model
of insulinomas, presumably through imatinib-mediated targeting of PDGF receptors on
pericytes.

[81]

This study also provided evidence of the important role of PDGF-BB and

PDGF-DD in pericyte recruitment to tumors. Together, these observations suggest that
pericytes represent an important target for the anti-VEGF treatment.
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Chapter 4
Investigation of Tumor IFP in a Xenograft Breast Cancer Model
The fact that most solid tumors possess a high interstitial tumor pressure, led us to propose
that tumor hypertension can be responsible for the tumor drug uptake which might be
responsible of tumor efficacy. Using a xenograft tumor model, we set out to investigate the
effect of tumor IFP using two doses of paclitaxel and bevacizumab, analyzing the efficacy of
the combination of anticancer drugs and transvascular drug transport.
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Material and Methods
Cell Line
Dr. Janet E. Price provided the GILM2 cell line. This cell line was originated from GI101A
human breast cancer cell line initially provided by Goodwin Institute for Cancer Research,
Inc. (Plantation, Florida)

[82]

Lung metastasis-derived lines were established as follows; the

lung from mice injected with GI101A cells were minced finely and plated in culture dishes.
The resulting culture was named GILM1. This cell line was expanded in culture and injected
into mice. Metastases in the lungs of these animals were isolated and the procedure repeated
to produce the line GILM2 (a pool from the metastases of three mice). [83] This new cell line
demonstrated a higher anchorage-independent growth, tumorigenicity and spontaneous lung
metastasis than GI101A cells. [84]
For the experiments in vitro, we seeded 2 x 106 cells/ml and cells were maintained in
monolayer culture in Dulbecco’s minimum essential medium-F12 medium (DMEM/F12)
supplemented with 10% FBS, L-glutamine, 5% v/v insulin-selenium-transferrin supplement
(Sigma Chemical Co., St Louis, Missouri). Actual cell numbers were calculated by
multiplying diluted times compared with initial cell numbers. Cell viability % = viable cell
numbers/total (viable + dead) cells numbers x 100%. Inhibition % = (control groupsexperimental groups)/control groups for viable cell numbers x 100%. Differentiation was
evaluated by nitroblue tetrazolium (NBT, Sigma) reduction test.
To determine the in vitro tumor growth inhibition of GILM2 cells by the reagents,
cells were cultured in monolayer culture. GILM2 cells were plated in 96-well culture plates
at an initial density of 5 x 103 cells per well, and allowed to attach for 24 h. The culture
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medium was then changed and the cells were incubated for a further 72 hr in different culture
conditions: medium alone, with paclitaxel (1 - 10 nM), with bevacizumab (0.1 - 10 ug/ml) or
a combination of these agents. Relative cell numbers were determined using MTT. Aliquots
of 40 ul of a 5 ug/ml solution of MTT were added to each well and incubated for 2hr; the
medium was then aspirated and the cells lysed by the addition of 100 ul DMSO. The
conversion of MTT to formazan in metabolically viable cells was monitored with a MR-5000
microtiter plate reader to read at 570 nm (Dynatech, Inc Chantilly, VA). All assays were
performed in triplicate, with a minimum of three independent experiments.

Animals
Female athymic NCr-nu mice were purchased from the NCI-Frederick Cancer Research
Faculty (Frederick, Maryland). The mice were housed in a specific pathogen-free facility and
used at seven to eight weeks of age. The care and use of laboratory animals were in
accordance with the principles and standards set forth in the Principles for Use of Animals
(NIH Guide for Grants and Contracts), the Guide for the Care and Use of laboratory animals
and the provisions of the Animal Welfare Acts. The ACUF Protocol (#11-07-12731) was
approved on November 21. 2007.

Reagents
Paclitaxel (Taxol, Bristol Myers Squibb) was obtained from the MD Anderson Cancer
Center central pharmacy. It was stored at room temperature and diluted with phosphate
buffered saline (PBS). Two doses of paclitaxel were defined: low dose (LD) 15 mg/kg twice
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a week, and high dose (HD) 24 mg/kg twice a week. Bevacizumab (Avastin, Genentech)
was obtained from the MD Anderson Cancer Center central pharmacy and was stored at 4°C.
Two doses of bevacizumab were defined: low dose (LD) 5 mg/kg twice a week, and high
dose (HD) 10 mg/kg twice a week. Both experiments were conducted separately.
In the LD experiment mice were randomized into four groups (n=10/group) and the
following treatments were initiated: (a) vehicle control (PBS i.p. injection twice a week), (b)
paclitaxel (15 mg/kg i.p. injection twice a week), (c) bevacizumab (5 mg/kg i.p. injection
twice a week, and (d) the combination of paclitaxel and bevacizumab (same doses, i.p.
injection twice a week).
In the HD experiment mice were randomized into four groups (n=10/group) and the
following treatments were initiated: (a) vehicle control (PBS i.p. injection twice a week), (b)
paclitaxel (24 mg/kg i.p. injection twice a week), (c) bevacizumab (10 mg/kg i.p. injection
twice a week, and (d) the combination of paclitaxel and bevacizumab (same doses, i.p.
injection twice a week). Following 3 weeks of therapy, mice were sacrificed. Body weights
were recorded, and tumors were weighed and collected.
The description of the treatment is depicted in Figure 4.
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Figure 4 - Description of the Experimental Treatment

Details of the treatment
ACUF Protocol # 11-07-12731
180 Mice
45 Mice
mfp*

Tumor /
Cell
Injection:

2x106 GILM2 Cells/0.1 ml

Treatment Regimen:

PBS
0.1 ml**

45 Mice

45 Mice

45 Mice

mfp

mfp

mfp

2x106 GILM2 Cells/0.1 ml

Bevacizumab
LD 5 mg/Kg/twice week
HD 10 mg/Kg/twice week

2x106Cells GILM2/0.1 ml 2x106 GILM2 Cells/ 0.1 ml

Paclitaxel
Bevacizumab/Paclitaxel
LD 15 mg/kg/twice week
Same combination
HD 24 mg/kg/twice week

Mice examined daily for size of tumor and signs of lethargy,
loss of grooming habits, loss of appetite, and loss of activity,
anorexia, >10% weight loss, ascites and dyspnea. Mice will be
sacrificed when mice demonstrate signs of lethargy.
Mice sacrificed at various times as indicated in following pages.
*mfp:mammary fat pad
**Total Volume of IP drug injected 0.1 ml for all drugs.

LD: low dose; HD: high dose
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Tumor Growth
For all in vivo experiments, tumor cells in exponential growth phase were harvested by brief
exposure to 0.25% trypsin in 0.02% EDTA, then washed and resuspended in Ca2+ and Mg2+
free PBS, to give a dose of 2.5 x106 cells in 100µl. This dose of cells was injected into the
mammary fat pat (mfp) of mice. Local tumor growth was measured at two weekly intervals,
using calipers, recording two perpendicular diameters to calculate the mean tumor diameter.
Tumors were established by implantation of human breast cancer cell line GILM2
(dose 2x106 cells/0.1 ml) into mammary fat pad (mfp) in 5 – 6 weeks old female mice. Mice
were monitored twice a week for tumor growth, and experiments were performed on week 45 after injection on mice bearing tumors ranging in size between 0.5 cm3 and 1 cm3.
Mice were kept under specific pathogen-free condition. Sterilized food and tap water
were given ad libitum. Drug efficacy was assessed in terms of tumor volume and body
weight, and was recorded three times a week. Tumor volume were calculated as V = a2 x b x
π/6, where a and b equal the short and the long diameter of the tumor, respectively. Once
tumors became median size of 500 mm3, approximately at day 45 of the experiment, mice
were treated with i.p. injection of paclitaxel and bevacizumab twice a week. Measured tumor
of 1.5 cm mean diameter were either surgically removed and the incision closed with wound
clips, or the mouse was euthanized. All mice were necropsied, and tumors removed for
culture and/or histopathological analysis after three weeks of treatment. All in vivo
experiments were conducted in accordance with the guidelines of the MD Anderson Cancer
Center Animal Care and Committee.

32

Interstitial Fluid Pressure Measurement.
Tumor IFP was measured using the ultraminiature tipped catheter described by Dr. Ozerdem.
[85]

Following general anesthesia with isoflurane (1.5%-2.5% isoflurane delivered at 1-2

L/min) ultraminiature transducer-tipped catheter in which the sensor is side-mounted at the
tip: SPC-320 transducer (2 French in size, 0.66 mm in diameter) and the ultraminiature
pressure transducer were introduced into the tumor protected with 18-gauge needle to the
core of the tumor. The Mikro-Tip (PSC-320 Millar) was connected to transducer Millar. The
transducer was connected to a PowerLab 8/30 amplifier and the data was imported into
software to a Macintosh computer. Records of tumor IFP were done in mm Hg. The needle
was removed slowly while the sensor was introduced into the center of the tumor. The
location of the center of the tumor is estimated by dividing the caliper-measured diameter of
tumor in half. This procedure was performed at baseline and then twice per week. Each
measurement lasted approximately 3 to 5 minutes. The tumor measurement equipment is
depicted in Figure 5.
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Figure 5 - Equipment to assess the IFP with ultraminiature pressure transducer.
A. The ultraminiature transducer (arrow) is introduced percutaneously into a surface of the
tumor in a protective metal guide (18-gauge needle) (arrowhead).
B. The needle is withdrawn slowly, while the sensor is introduced into the center of the
tumor. The location of the center of the tumor is estimated by dividing the caliper-measured
diameter of tumor in half. The transducer can be marked for millimeter gradation using
standard fine point pens.
C. Handling of the needle guide and transducer is very easy during microsurgical procedures
on mice. Scale bar = 600 µm. Pictures A, B, and C were obtained from Ozerdem and
Hargens. [85]
D. Millar catheter introduced into the 18-gauge needle. F. Mac Laptop, connected to
PowerLab 8/30 amplifier and the data was imported into software to a Macintosh computer.
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Figure 5: Interstitial fluid pressure measurement with ultraminiature pressure transducer.
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Immunohistochemistry Analysis
Tumor tissue was fixed in 10% buffered formalin for paraffin embedding, or frozen in OCT
compound (Miles Laboratories, Elkhart, Indiana) in liquid nitrogen. For assessment of blood
vessel quantification, 5µm frozen tissue sections were cut, fixed in acetone and stained with
antibodies to CD31/PECAM-1 (PharMingen, Sand Diego, California) with fluorescent Alexa
647 antirat secondary antibody (Invitrogen). This experiment has been described elsewhere.
[86]

Non-specific IgG was used for control reactions. Areas of sections with the highest

numbers of stained capillaries and small venules were identified by scanning the sections at
low power magnification (40X). Images of 10 fields at higher magnification (100X) from
these selected areas were captured using a digital camera and stored for analysis.
ImageJ software (National Institute of Health) was used to assess vessel area, vessel
diameter, and length. Vessel area was calculated from number of pixels stained with CD31
per high-power field. Vessels diameter and length were calculated from measuring pixels of
each vessel at its largest diameter or length and converting pixels to micrometers. Sections
were counterstained with hematoxylin. The CD31 and pericyte staining, area was quantified
(40X objective, 20 fields from each slide) by using ImageJ software (National Institute of
Health).
Sections of paraffin-embedded tumor that had been formalin-fixed were used to identify
cleaved-caspase 3. Immunohistochemistry using the rabbit anti-cleaved caspase 3 antibody
was performed on deparaffinized tissue sections using a routine avidin-biotinimmunoperoxidase technique [Vectasin Elite avidin-biotin-immunoperoxidase kit reagents
(Vector Labs, Burlingame, CA)]. Before incubation with the primary antibody (1:200
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dilution as supplied by the manufacturer), tissue sections were subjected to heat-induced
epitope retrieval by incubation in a Ph 8.0 0.01 M EDTA solution for 10 min in a vegetable
steamer, followed by 20-min cool-down and treatment with 3% hydrogen peroxide before
antibody application. Microscopy: fluorescence images were prepared using a Zeiss
Axioplan 2 microscope equipped with phase-contrast optics and with rhodamine and UV
channel filters. Images were recorded using either a Dage 300 monochrome CCD camera or
a Zeiss Axiocam CCD camera, and composite figures were prepared using Adobe Photoshop.

Immunofluorescence double staining for CD31 and Desmin
Sections were fixed in cold acetone for 10 min, blocked with protein blocker for 20 min at
room temperature, incubated with CD31 antibody (1:400; PD PharMiagen) overnight at 4°C
followed by incubation with Alexa Fluor 594-conjugated with anti-rat antibody (1:1,000;
Invitrogen) for 1 hour at room temperature. After washing with PBS, samples were incubated
with desmin antibody (1:400; DakoCytomation) for 1 hour and followed by incubation with
Alexa Fluro 488-congugated anti-rabbit antibody (1:1,200; Invitrogen) for 1 hour at room
temperature. Samples were counterstained with Hoechst for 5 min and mounted.

Hypoxia Measurement
Pimonidazole hydrochloride (HypoxyProbeTM, 100 mg/kg/0.2 ml PBS) was administered IP
to tumor-bearing mice and this agent is metabolized and bound to hypoxic cells within the
tumor.

[87]

Three hours after injection, tumors were excised and frozen in liquid nitrogen.

Frozen sections (10µm thick) from the central regions of tumors were fixed for 15 min in 4%
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FBS, 5% nonfat milk, and 0.1% Triton X-100 in PBS. Slides were incubated for 1 hour at
room temperature with an FITC-conjugated monoclonal antibody against pimonidazole
(1:20) (Millipore) and counterstained with 50 nM propidium iodine (PI). FITC and PI
fluorescent signals for entire tumor sections (one section per tumor) were acquired on a
Nikon Eclipse E800 microscope equipped with motorized scanning stage, a 12-bit QImaging
camera (QImaging, Burnaby, Canada)

Lectin Perfusion and Tumor Vascular Staining.
Mice were anesthetized and injected intravenously (tail vein injection) with 100 µl of
fluorescein Lycopersicon esculentum lectin (Vector Laboratories). Ten minutes later, we
perfused mice through the ascending aorta with 4% paraformaldehyde for 2 minutes. Tumors
were extracted, placed in 4% paraformaldehyde for another 2 hours followed by immersion
in 30% sucrose/PBS overnight. Tumor samples were then embedded in OCT, and cryostat
sectioned for visualization using confocal fluorescence microscopy.

Intratumoral Drug Distribution of Labeled-Paclitaxel
In this aim, we aimed to investigate the influence of bevacizumab on the antitumor activity of
paclitaxel and the intratumoral distribution in GILM2 model. This aim was conducted under
the guidance of Dr. William G. Bornmann, Professor of Experimental Therapeutics. Thirty
mg of paclitaxel were conjugated to Dansyl dye. Reconstitution was done in DMSO
following by i.p. injection of 24 mg/kg of labeled-paclitaxel. Dansyl chloride or 5(dimethylamino) naphthalene-1-sulfonyl chloride is a reagent that reacts with primary amino
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groups in both aliphatic and aromatic amines to produce stable blue- or blue-greenfluorescent sulfonamide adducts. The absorption value was always taken at the maximum
that appears between 310 nm and 350 nm. The conjugations of dansyl chloride with
paclitaxel in the tumor possess a dark blue color.

Determination of Transcapillary Transport of Paclitaxel into the Tumor Tissue Using Liquid
Chromatography/Mass Spectrometry (LC/MS)
LC/MS is a simple, rapid and sensitive analytical method for quantifying paclitaxel in tissue
homogenates.[88] This aim was conducted under the guidance of Dr. Timothy L. Madden,
Director of the Pharmacology and Analytical Facility. This method combines a one-step
liquid-liquid sample extraction with ESI ± MS/MS detection to achieve the selective and
specific quantization of paclitaxel. The assay has been fully validated by previous preclinical
studies at MD Anderson Cancer Center. [89, 90]

Statistical Analysis
All experiments were repeated at least two times on different occasions. The results are
presented as the mean ± 95% confidence intervals for all values. All data were analyzed
using GraphPad Prism 4 (GraphPad Software, Inc) and the Mann-Whitney nonparametric t
test. A p value of <0.05 was considered statistically significant.
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Results

The experiment aims and the diagram of treatment plan is depicted in Figure 6.
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Figure 6

Flow Sheet of the Treatment
In vivo studies:
IFP*: During the first week of experiment a total of 3 measurements, and during the 2nd and 3rd weeks one
measurement each week.
Perfusion study: During the first week of the experiment a total of 2 assays, and during the 2nd and 3rd weeks
one assay each week.
Hypoxia study: During the first week of the experiment a total of 2 assays, and during the 2nd and 3rd weeks
once each week.
Tumor Volume measurement: two times a week.
Diagram of Treatment Plan:
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In vitro treatment of culture cells using paclitaxel and bevacizumab
The GILM2 breast cancer human cell line was used for this experiment. The cells were
determined to be free of mycoplasma and 17 different murine viral pathogen before use.
Clonogenic Assay
The combination of paclitaxel plus bevacizumab and paclitaxel as single agent results in no
visible colonies. (Figure 7 a) The bevacizumab and control dishes have colonies in the same
proportion. The interpretation of this experiment is that the GILM2 breast cancer cells are
sensitive to paclitaxel, and insensitive to bevacizumab. One conclusion of this experiment is
the absence of bevacizumab sensitivity response might be mediated by the lack of VEGF
receptors in the tumor cell.
MTT Assay
We performed a 3-(4,5-dimethylthiazol-2-yl)-2,5-dephenyltetrazolium bromide (MTT) to
correlate with the clonogenic assay performed. Several serial dilutions of bevacizumab and
paclitaxel plus bevacizumab were performed and we found similar results to those of the
clonogenic assay. The plots in Figure 7 b, demonstrated that GILM2 is insensitive to
increasing doses of bevacizumab as single agent as well in combination with paclitaxel.
GILM2 cells are sensitive to paclitaxel. Increasing paclitaxel doses produced a dose response
curve.
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Figure 7
a. Clonogenic assay performed in 4 Petri dishes, with GILM2 1 x 102 breast cancer
cells. The control group was treated with PBS only, the paclitaxel flask was treated with 5
nM of paclitaxel, the bevacizumab flask was treated with 10 μg/ml, and the
paclitaxel/bevacizumab flask was treated with 5 nM of paclitaxel and 10 μg/ml. The control
and bevacizumab dishes showed a persistence of colonies. The paclitaxel and combination of
paclitaxel and bevacizumab showed a complete absence of visible colonies.

b. Proliferative assay
Upper graphic: Serial dilution of bevacizumab and paclitaxel in combination with
bevacizumab were placed in 96-well microplate.
Lower graphic: the breast cancer tumor cell line GILM2 in exponential growth was exposed
to increasing nanomolar concentration of paclitaxel. Paclitaxel showed a dose response curve
with an estimation of IC50 value of 5.2.
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Figure 7a: In vitro activity of paclitaxel and bevacizumab. Clonogenic Assay
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Tumor growth inhibition by the combination of paclitaxel and bevacizumab
To determine whether the treatment with paclitaxel and bevacizumab is effective to eradicate
tumors in vivo, we conducted two independent experiments using two different
chemotherapy schedules: low dose (LD) and high dose (HD). We first tested the effects of
the low dose of paclitaxel (15 mg/kg) plus bevacizumab (5 mg/kg) on GILM2 tumor
xenografts. Overall, the therapies were well tolerated by the mice. Compared with the control
mice, a 3% to 9% weight decrease was noted in the treatment groups with the greatest
decrease observed in the combination group (data not shown). No mice in any of the
treatment groups appeared moribund or ill before sacrifice and no hemorrhagic or infection
complications were observed. Not all mice developed primary mfp tumors (85%
tumorigenicity).
LD Experiment: Mice treated with the combination of paclitaxel and bevacizumab inhibited
tumor growth by 41% reduction mean of tumor volume of the mfp breast tumors compared
with the tumors in the control group. (Figure 8 a and b) However this reduction was not
statistically significant (t test p = 0.1720). The combination of paclitaxel and bevacizumab
substantially inhibited tumor growth more than either therapy alone. Paclitaxel single agent
produced a reduction of 32.77% compared with control. Finally, treatment with bevacizumab
produced minimal effect on the tumor control with reduction on 8% the mean of tumor
volume. Tumor weight mirrored the changes observed for tumor volume (data no shown).
HD Experiment: Mice treated with paclitaxel and paclitaxel plus bevacizumab inhibited
tumor growth by 56.1% in the mean volume of the mfp breast tumors compared with the
tumors in the control group. (Figure 8 c and d) The difference of tumor volume between the
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combination of paclitaxel plus bevacizumab and control group was statistically significant. (t
test p = 0.0183) The treatment with paclitaxel as single agent reduced the tumor volume by
50% (t test p = 0.0270). Bevacizumab reduced the tumor volume by 31.9%; however,
compared with control group this is not statistically significant. (t test p = 0.1572)
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Figure 8 a and b: In vivo Activity of Low Dose Treatment
Figure 8 c and d: In vivo Activity of High Dose Treatment.
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Figure 8 - In vivo activity of paclitaxel and bevacizumab in GILM2 breast cancer tumor
xenografts
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Treatment with the combination of paclitaxel and bevacizumab decreases the tumor IFP
Basal Tumor IFP
Tumor IFP (mmHg) was evaluated in a wide range of experimental models at the baseline.
We found a positive correlation (Pearson r 0.4632; p = 0.0044) with tumor IFP and tumor
volume (mm3) (Figure 9 a).
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Figure 9

Correlation Analysis
Pearson r
95% confidence interval
P value (two-tailed)
R squared

0.4632
0.1587 to 0.6872
0.0044
0.2145
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Effect of Treatment on Tumor IFP
GILM2 breast cancer cells were implanted into mfp. We tested whether treatment with LD or
HD decreased the tumor IFP. In the LD experiment there was no statistically significant
difference between arms comparing day 1 to day 21. (Figure 9b) Tumor IFP fluctuated
during treatment arms especially with paclitaxel; however, the IFP level returned to similar
baseline point. In the HD group, the combination of paclitaxel and bevacizumab resulted in
statistically significant reduction of IFP (p = 0.0068) compared with the other the arms.
(Figure 9 c)
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Figure 9b: Tumor IFP in the Low Dose Group
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Figure 9c: Tumor IFP in the High Dose Group
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Combination of paclitaxel and bevacizumab significantly increase tumor apoptosis.
It is now clear that caspase activation (cleavage of procaspase to active caspase) is a hallmark
of almost all apoptotic systems. We tested whether induction of tumor cell death might also
contribute to the antitumor activity of bevacizumab in combination with paclitaxel.
These results (Fig 10) suggested that induction of apoptosis by the combination of paclitaxel
and bevacizumab compared with either agent alone or vehicle, might contribute, at least in
part, to the inhibition of tumor growth.
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Figure 10 - Detection of cleaved caspase 3 in apoptotic cells in paraffin sections.
Localization of cleaved caspase 3 in deparaffinized sections of formalin –fixed tissues.
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Figure 10:
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Combination of paclitaxel and bevacizumab increases the diameter of tumor vessels and
decrease the pericyte coverage.
To assess whether neoplastic cell loss would decompress blood vessels, we measured vessel
diameter in GILM2 mfp tumors. Paclitaxel increased the diameter of blood vessels at day 7,
14 and 21; however, there were no changes in vessel density. The vascular diameter of
treated tumor was increased significantly when bevacizumab was added to paclitaxel,
doubling the vascular diameter and indicating that the vascular surface area increased
approximately

by

2-fold.

Next,

we

examined

pericyte

coverage

using

dual

immunofluorescence staining for CD31 and desmin. In normal tissues we found that small
vessels (venules and capillaries) were covered extensively by irregularly shaped pericytes
that were associated tightly with the endothelial cells. We found that pericytes were localized
in the growing tips or angiogenic “sprouts” of new blood vessels. (Figure 1 b) However,
tumor vessels were morphologically abnormal and tortuous in shape with irregular pericyte
coverage. Although most tumor vessels had pericyte coverage, the pericytes were attached
loosely and had extensions projecting both toward the endothelial cells and the tumor stroma.
After one week of treatment with paclitaxel with and without bevacizumab, there was an
increase in pericytes covering the blood vessels and also extending into the tumor stroma.
(Figure 11 a) The pericyte recruitment might be secondary to tissue stress after treatment
with chemotherapy. Subsequently, after 2 weeks of treatment, the blood vessels become
enlarged, with patchy endothelial coverage and small amounts of pericytes. (Figure 11 b) At
the end of third week of treatment, the group treated with the combination of paclitaxel and
bevacizumab were characterized by absence of lumen of blood vessels and practically
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complete disappearance of pericytes. This effect is more pronounced in the group that
received the combination of paclitaxel and bevacizumab than the group that received
paclitaxel single agent. (Figure 11c) The stained area in 20 fields was quantified by using
ImageJ software. Mean ± SEM (5 mice each) are shown. ∗, P < 0.01 (Student’s t test).
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Figure 11 - performed to visualize endothelial cells and pericytes. Images were taken at
original magnification (X400). Pericyte coverage of small vessels in breast carcinoma. The
percentages of vessels with at least 50% coverage of associated desmin-positive cells were
counted.
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Figure 11a: Immunofluorescence Analysis of Paclitaxel and Paclitaxel plus
Bevacizumab over Three Weeks Treatment
Paclitaxel Single Agent

Paclitaxel plus Bevacizumab

a.

b.

c.
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Figure 11 b: Quantification of endothelial cells, pericytes and apoptosis during the treatment
with paclitaxel and bevacizumab.

Figure 11 c: Quantification of Blood vessel characteristics.
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Tumor distribution of labeled-paclitaxel improved with the addition of bevacizumab.
To assess whether pretreatment with bevacizumab is associated with tumor concentration of
paclitaxel, we studied paclitaxel distribution in GILM2 tumor xenografts. The distribution of
labeled-paclitaxel within GILM2 xenografts was observed by examining tumors excised at a
range of time points after i.p. administration of the drug. Tumor cryosections were imaged
and stained immunohistochemically for combinations of paclitaxel, and endothelial cell
marker CD31 (red).

Distribution of paclitaxel through tumors. Mice bearing GILM2 xenografts were given single
i.p. doses of 24 mg/kg labeled-paclitaxel. A group of mice (4 per group) received
bevacizumab 10 mg/kg and other group received PBS (control). Representative high
resolution composite images for whole tumor sections obtained 2 to 2.5 mm from the tumor
edge were generated with a magnified portion of an untreated control tumor shown in Figure
12. Similar images of treated tumor show paclitaxel-labeled (blue) proximal to vasculature
(CD31 in red)
As shown in Figure 12, paclitaxel distribution into the tumor tissue was, in general, higher in
the bevacizumab treated group, with the difference in mean paclitaxel tumor concentration
between the groups reaching statistical significance at 24hs and 48 hs.
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Figure 12 - Distribution of labeled-paclitaxel into the tumor
a. Labeled-paclitaxel and vessels analysis on cryosections of GILM2 xenografts tumors in
paclitaxel and paclitaxel plus bevacizumab treated. Representative images show differences
in vessel morphology with CD31 staining. Intratumor distribution of labeled-paclitaxel (blue)
and nuclear staining with Cytoxgreen (green).
b. Graphical representation of image analysis of intratumor paclitaxel distribution. Bars
represent means values ±SEM (n = 4 per group). * P < .05, versus control.
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a. Effect of Bevacizumab in Tissue Paclitaxel Distribution
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b. Quantification of Labeled-Paclitaxel
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LC/MS Analysis
In this aim, we documented the amount of paclitaxel accumulation in the tumor and this was
directly analyzed by LC/MS. We used ANOVA test to determine whether or not there is a
statistically significance difference among the means of two group.
Low Dose Experiment:
Eighteen mice were randomized in two arms: paclitaxel 15 mg/kg, and paclitaxel (same dose)
plus bevacizumab (5 mg/kg). At the end of each week, 3 mice were sacrificed and tumor
removed. The comparison between the single agent paclitaxel versus the combination
paclitaxel and bevacizumab was statistically significant (1 way ANOVA; p = 0.0457)
High Dose Experiment:
Eighteen mice were randomized in two arms: paclitaxel 24 mg/kg, and paclitaxel (same dose)
plus bevacizumab (10 mg/kg). At the end of each week, 3 mice were sacrificed and tumor
removed. The comparison between the single agent paclitaxel versus the combination
paclitaxel and bevacizumab was not statistically significant (1 way ANOVA; p = 0.2224)
The comparison between the LD and HD was statistically significant (1 way ANOVA; p =
0.0257)
Our conclusion of this experiment was that intratumor paclitaxel accumulation
increases when low dose of paclitaxel and bevacizumab are given together compared with
paclitaxel single agent. At these low doses synergistic effect was demonstrated using this
drug combination. This synergistic effect was not observed when combinations of high doses
of same drugs were used.
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Figure 13 - Chromatography/Mass Spectrometry (LC/MS)
Eighteen samples were collected for LD and HD treatment.
a. Tissue paclitaxel accumulation in the low dose treatment.
b. Tissue paclitaxel accumulation in the low dose treatment.
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Figure 13: Liquid Chromatography/Mass Spectrometry (LC/MS)
a. Tissue paclitaxel accumulation in the low dose treatment

b. Tissue paclitaxel accumulation in the high dose treatment
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Discussion
Traditionally, cancer treatment has focused on targeting the tumor cells directly. It has,
however, become clear that tumor cells interact with and are dependent on surrounding
normal cell types in the tumor. So, targeting of non-malignant cell types, in parallel to the
tumor cells, might represent the future of cancer treatment. Combination therapy with an
antiangiogenic agent plus chemotherapy acts at multiple targets within the tumor, depriving it
of nutrients and oxygen (i.e. antivascular and antiangiogenic effects) and killing highly
proliferative tumor cells (i.e. cytotoxic effects) [91].
To summarize, the studies presented in this thesis have investigated the effects of the
combination of paclitaxel and bevacizumab on tumor growth, tumor IFP, transvascular
transport, and tissue paclitaxel distribution. It has conclusively demonstrated that the addition
of bevacizumab to paclitaxel increases the drug uptake, thus decreasing the IFP and
increasing significantly the tissue apoptosis.
It is believed that in the presence of a normal vasculature paclitaxel crosses
membranes by diffusion; however, in tumors, convective transport is influenced by changes
in IFP. In this study, the tumor IFP decreased significantly when paclitaxel is combined with
bevacizumab. In contrast to some early animal model studies demonstrating that anti-VEGF
agent decreases the tumor IFP,

[75] [76]

our observation together with other authors

[92]

demonstrated that single agent of anti-VEGF (bevacizumab) does not affect the tumor IFP
Our work as well the work of others [93] has shown that tumor IFP measurements can
predict tumor response in patients. The mechanisms responsible for the changes in tumor IFP
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during treatment are poorly understood. This study provides insights into the interrelationship
among neoplastic cells, tumor vasculature, tumor IFP, and drug uptake by the tumor.
Chemosensitization is the ability to augment the effects of standard chemotherapy.
One of the possible mechanisms for chemosensitization is improving intratumoral
chemotherapy concentrations by increasing total or regional delivery of chemotherapy to the
tumor. This mechanism potentially leads to a decreased tumor IFP. However, results from
two different groups

[94, 95]

demonstrated that the induction of apoptosis by the action of

taxanes -docetaxel and paclitaxel, causing and decompressing blood vessels can also reduce
tumor IFP. As antiangiogenic agents are generally cytostatic rather than cytoreductive,
combinations involving conventional cytotoxic chemotherapies may be useful for
maximizing therapeutic activity. The net outcome of a combination therapy is determined by
the balance between antiangiogenic potential and cytotoxicity. In this preclinical work, we
found that low dose combination of paclitaxel plus bevacizumab produces a synergistic effect
with increased intra-tumor paclitaxel concentration when bevacizumab is added. In contrast,
the high dose of treatment produced no statistical significant increment of paclitaxel
accumulation into the tumor. But at the same time, effective tumor control was seen only
with the high doses of treatment. The same effect has been seen in the clinic where improved
clinical responses were observed when conventional chemotherapy is combined with lowdose of bevacizumab compared with high dose bevacizumab. [96]
There are two lines of investigation that would benefit from further studies. First,
there is much to do to fully understand the mechanism behind the increased IFP of solid
tumors and to find ways to lower tumor IFP. Most importantly, the concept of lowering
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tumor IFP and improving tumor efficacy needs to be validated in the clinic. So far, there is
only one study demonstrating that the IPF was an independent prognostic parameter to
disease-free survival in cervical carcinoma patients treated with radiation therapy. A
decreased IFP at early phase of the beginning of the neoadjuvant treatment can be used as
early surrogate of tumor response in breast cancer patients. This effect would improve the
current tumor assessment and impact in the management of breast cancer patients treated
with primary systemic therapy.
Second, we need to repeat the experiment using the same preclinical protocol
assessing tumor response by dynamic contrast enhanced magnetic resonance imaging (DCEMRI). In our prior experience with DCE-MRI we found multiple technical difficulties related
to the site of implantation of mfp and the experiment found no differences in blood flow and
permeability, besides good tumor control in the combination arm with paclitaxel and
bevacizumab. Tumor blood flow is highly heterogeneous. It is not the total blood flow, but
the distribution of blood flow that determines the distribution of a drug or oxygen in tumors.
Therefore, the global (total) blood flow, as estimated by the currently available resolution of
DCE-MRI or CTs, does not inform us about the degree of spatial heterogeneity in vascular
normalization of distribution. An alternative approach will be investigated in the future using
an ultrasound Doppler to characterize the blood vessels morphology. Thus, there is real
necessity to improve our imaging techniques with higher resolution of the temporal changes
in blood flow and other physiological parameters. This is a real unmet need to definitively
establish the effects of antiangiogenic treatment on vascular function.
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Neoadjuvant chemotherapy for the treatment of breast cancer has been used for
almost four decades and it is considered the initial component of the multidisciplinary
approach for the treatment of patients with locally advanced and large operable breast cancer.
This approach has been proven save and as effective as adjuvant therapy. Although of the
more convincing arguments for the neoadjuvant treatment its value as an in vivo test for drug
sensitivity, the major advantage of this treatment modality is the increase of the breastconservative approach. Several studies in breast cancer patients treated with neoadjuvant
treatment showed that drug sensitivity correlates with survival. Several aspects of the
neoadjuvant therapy remain to be confirmed and validated in prospective trials. After many
years of investigations, many questions remain regarding the best chemotherapy, sequence of
different regimens, and length of treatment. Recently, neoadjuvant chemotherapy provides an
ideal scenario for determining prognostic and predictive factors of response to specific
regimens. The pathologic complete response (pCR) is the major surrogate endpoint;
however, pCR occurs several months after the initiation of neoadjuvant chemotherapy. We
believe that early changes in the tumor IFP might be correlated with tumor response. A report
by Milosevic and collaborators

[59]

has shown that the tumor IFP can predict survival in

patients with cervix cancer treated by radiation therapy, independently of other clinical
factors, suggesting that it is a potential useful parameter of response. Currently, I have
developed an exploratory biomarker study to analyze changes in tumor IFP during
neoadjuvant treatment in breast and malignant melanoma patients. I am planning to use the
same IFP instrumentation for intratumor hypertension assessment that was utilized in this
preclinical experiment.
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The administration of single agent anti-VEGF such as bevacizumab, sorafenib and
sunitinib has demonstrated a modest tumor activity in MBC with responses rate of 6%, 2%,
and 11%, respectively. Results from phase III clinical trials demonstrated that bevacizumab
in combination with chemotherapy had clinical benefit in previously untreated breast, lung
and colorectal cancer when compared with standard chemotherapy alone.

[97-99]

Although

three large randomized clinical trials in advanced breast cancer patients using paclitaxel plus
bevacizumab have demonstrated positive results increasing consistently the progression free
survival, the FDA has recently questioned the efficacy of bevacizumab. Several preclinical
studies using animal models have demonstrated that the combination of anti-angiogenic
agent with cytotoxic drug is superior compared with single agent treatment. After two years
working with animal models using different combination of the aforementioned drugs, this
study suggests that bevacizumab might modify temporarily the transvascular transport of the
cytotoxic agent, thus acting as chemosensitizer more than cytostasis.
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